Review

u266 b1 human multiple myeloma b lymphocyte cell line (ATCC)

ATCC is a verified supplier

ATCC manufactures this product

About

News

Press Release

Team

Advisors

Partners

Contact

Bioz Stars

Bioz vStars

Buy from Supplier

Structured Review

ATCC u266 b1 human multiple myeloma b lymphocyte cell line
U266 B1 Human Multiple Myeloma B Lymphocyte Cell Line, supplied by ATCC, used in various techniques. Bioz Stars score: 97/100, based on 1684 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+myeloma+cell+lines+u266/U266B1/pm41898552-244-1-13
Average 97 stars, based on 1684 article reviews

u266 b1 human multiple myeloma b lymphocyte cell line - by Bioz Stars, 2026-11

97/100 stars

Images

Cell Culture:

Article Title: LncRNA MALAT1/miR-181a-5p affects the proliferation and adhesion of myeloma cells via regulation of Hippo-YAP signaling pathway
Article Snippet: .. Cell culture Human bone marrow stromal cell lines HS-5, and Human myeloma cell lines U266, MM.1S, RPMI8226 were purchased from the American Type Culture Collection (ATCC). .. Cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM) (Gibco, Grand Island, NY, USA) containing 10% fetal bovine serum (FBS) (Hyclone, Australia) and 1% antibiotic-antimycotic solution at 37°C in a humidified incubator with 5% CO 2 .

Article Title: Network-Based Analysis of Bortezomib Pharmacodynamic Heterogeneity in Multiple Myeloma Cells
Article Snippet: .. Cell Culture and Reagents The human myeloma cell lines U266 (catalog number TIB–196), RPMI8226 (catalog number CCL–155), MM.1S (catalog number CRL–2974), and NCI–H929 (catalog number CRL–9068) were purchased from American Type Culture Collection (ATCC; Manassas, VA). .. Cells were maintained in culture in RPMI 1640 medium (catalog number 30–2001; ATCC) supplemented with fetal bovine serum (catalog number 30–2020; ATCC) and penicillin-streptomycin (BioWhittaker; Lonza, Walkersville, MD).

other:

Article Title: Network-Based Analysis of Bortezomib Pharmacodynamic Heterogeneity in Multiple Myeloma Cells
Article Snippet: f. Statistical Analysis Spearman’s rank correlation coefficient matrix signatures were calculated between cell viability values under bortezomib treatment and relative protein expressions for all four cell lines in SigmaPlot (version 12.0; Systat Software Inc., San Jose, CA).

FACS:

Article Title: Clinical and prognostic role of annexin A2 in multiple myeloma.
Article Snippet: Normal BM plasma cells and myeloma cells were purified as described previously.6-8 Aliquots of unpurified whole BM of myeloma patients (n 154) and healthy donors (n 7) were obtained after NH4 lysis.12 Alternate aliquots were subjected to FACS sorting (FACSAria; BD Biosciences) in CD3 , CD14 , CD15 , and CD34 cells. .. Peripheral CD27 memory B cells (n 11) were FACS sorted as described previously.33 The human myeloma cell lines U266, RPMI-8226, LP-1, OPM-2, SK-MM-2, AMO-1, JJN-3, NCI-H929, KMS-12-BM, KMS-11, KMS-12-PE, KMS-18, MM1.S, JIM3, KARPAS-620, L363, and ANBL6 were purchased from the German Collection of Microorganisms and Cell Cultures (Braunschweig, Germany) and ATCC. .. The XG lines were generated at Inserm U1040 (Montpellier, France).34 Polyclonal plasmablastic cells (n 10), osteoclasts (n 7), and mesenchymal stromal cells (n 15) were generated as described previously.6,35,36 Mesenchymal stromal cells (n 8) were in vitro differentiated into osteoblasts according to published protocols.37

Image Search Results

Identification of constructed TCF4−/+ U266 and MMSA−1−/+ U266 stable cell lines and MMSA-1 mRNA and protein levels in TCF4−/+ U266 cells 1: U266 cells; 2: TCF4− U266-NC; 3. TCF4− U266 cells; 4: TCF4+ U266-NC; 5. TCF4+ U266 cells

Journal: Annals of Hematology

Article Title: MMSA-1 is regulated by Wnt/TCF4 and involved in multiple myeloma progression and invasion via RAS/RAF signaling pathway

doi: 10.1007/s00277-026-06740-8

Figure Lengend Snippet: Identification of constructed TCF4−/+ U266 and MMSA−1−/+ U266 stable cell lines and MMSA-1 mRNA and protein levels in TCF4−/+ U266 cells 1: U266 cells; 2: TCF4− U266-NC; 3. TCF4− U266 cells; 4: TCF4+ U266-NC; 5. TCF4+ U266 cells

Article Snippet: Human multiple myeloma cell line U266 and 293 T were purchased from Wuhan Procell Life Science&Technology Co., Ltd, both of which have been identified by Short Tandem Repeat (STR).

Techniques: Construct, Stable Transfection

Dual-Luciferase Report Assay results in different U266 cells

Journal: Annals of Hematology

Article Title: MMSA-1 is regulated by Wnt/TCF4 and involved in multiple myeloma progression and invasion via RAS/RAF signaling pathway

doi: 10.1007/s00277-026-06740-8

Figure Lengend Snippet: Dual-Luciferase Report Assay results in different U266 cells

Techniques: Luciferase

MMSA-1 and RAS co-localization and interaction in U266 cells 1: U266 cells; 2: MMSA−1− U266-NC; 3. MMSA−1− U266 cells; 4: MMSA−1+ U266-NC; 5. MMSA−1+ U266 cells

Journal: Annals of Hematology

Article Title: MMSA-1 is regulated by Wnt/TCF4 and involved in multiple myeloma progression and invasion via RAS/RAF signaling pathway

doi: 10.1007/s00277-026-06740-8

Figure Lengend Snippet: MMSA-1 and RAS co-localization and interaction in U266 cells 1: U266 cells; 2: MMSA−1− U266-NC; 3. MMSA−1− U266 cells; 4: MMSA−1+ U266-NC; 5. MMSA−1+ U266 cells

Techniques:

RAS downstream related molecule expressions in different U266 cells 1: U266; 2: MMSA−1− U266-NC; 3. MMSA−1− U266; 4: MMSA−1+ U266-NC; 5. MMSA−1 + U266

Journal: Annals of Hematology

Article Title: MMSA-1 is regulated by Wnt/TCF4 and involved in multiple myeloma progression and invasion via RAS/RAF signaling pathway

doi: 10.1007/s00277-026-06740-8

Figure Lengend Snippet: RAS downstream related molecule expressions in different U266 cells 1: U266; 2: MMSA−1− U266-NC; 3. MMSA−1− U266; 4: MMSA−1+ U266-NC; 5. MMSA−1 + U266

Techniques:

MMSA-1’s effect on U266 cells proliferation, migration and apoptosis A showed cloning formation assay result; B showed transwell assay result; C showed apoptosis related proteins expression and D showed mitochondrial apoptosis in different U266 cells. 1: U266; 2: U266 + CCCP-1; 3. MMSA−1− U266-NC; 4. MMSA−1− U266-NC + CCCP-1; 5. MMSA−1− U266; 6: MMSA−1− U266 + CCCP-1; 7. MMSA−1+ U266-NC; 8. MMSA−1+ U266-NC + CCCP-1; 9. MMSA−1 + U266; 10. MMSA−1 + U266 + CCCP-1

Journal: Annals of Hematology

Article Title: MMSA-1 is regulated by Wnt/TCF4 and involved in multiple myeloma progression and invasion via RAS/RAF signaling pathway

doi: 10.1007/s00277-026-06740-8

Figure Lengend Snippet: MMSA-1’s effect on U266 cells proliferation, migration and apoptosis A showed cloning formation assay result; B showed transwell assay result; C showed apoptosis related proteins expression and D showed mitochondrial apoptosis in different U266 cells. 1: U266; 2: U266 + CCCP-1; 3. MMSA−1− U266-NC; 4. MMSA−1− U266-NC + CCCP-1; 5. MMSA−1− U266; 6: MMSA−1− U266 + CCCP-1; 7. MMSA−1+ U266-NC; 8. MMSA−1+ U266-NC + CCCP-1; 9. MMSA−1 + U266; 10. MMSA−1 + U266 + CCCP-1

Techniques: Migration, Cloning, Tube Formation Assay, Transwell Assay, Expressing

Adhesion molecules and angiogenesis factors levels in different U266 cells A showed qRT-PCR result and B showed Western Blot result of adhesion molecules; C showed angiogenesis factors levels. 1: U266 cells, 2: MMSA−1− U266-NC; 3. MMSA−1− U266; 4. MMSA−1+ U266-NC; 5. MMSA−1+ U266

Journal: Annals of Hematology

Article Title: MMSA-1 is regulated by Wnt/TCF4 and involved in multiple myeloma progression and invasion via RAS/RAF signaling pathway

doi: 10.1007/s00277-026-06740-8

Figure Lengend Snippet: Adhesion molecules and angiogenesis factors levels in different U266 cells A showed qRT-PCR result and B showed Western Blot result of adhesion molecules; C showed angiogenesis factors levels. 1: U266 cells, 2: MMSA−1− U266-NC; 3. MMSA−1− U266; 4. MMSA−1+ U266-NC; 5. MMSA−1+ U266

Techniques: Quantitative RT-PCR, Western Blot

BBR decreases IgE secretion but not IgG secretion. The expression of IgE by IgE-producing myeloma cells, U266, was determined by ELISA following berberine (BBR) treatment at 10, 5, and 2.5 μg/mL compared to the equivalent concentration of DMSO (0 μg/mL) for 6 days ( A ). The expression of IgG by IgG-producing myeloma cells, ARH-77, was determined by ELISA, treated as U266 ( B ). N = 3–4, ** p ≤ 0.01, *** p ≤ 0.0001, ns = not significant. Each dot represents a single biological replicate.

Journal: Cells

Article Title: A Small Molecule Compound, Berberine Reduces IgE but Not IgG Production via Promoting miRNA-34a-p53 Axis

doi: 10.3390/cells14221799

Figure Lengend Snippet: BBR decreases IgE secretion but not IgG secretion. The expression of IgE by IgE-producing myeloma cells, U266, was determined by ELISA following berberine (BBR) treatment at 10, 5, and 2.5 μg/mL compared to the equivalent concentration of DMSO (0 μg/mL) for 6 days ( A ). The expression of IgG by IgG-producing myeloma cells, ARH-77, was determined by ELISA, treated as U266 ( B ). N = 3–4, ** p ≤ 0.01, *** p ≤ 0.0001, ns = not significant. Each dot represents a single biological replicate.

Article Snippet: The IgE-producing human myeloma U266 cell line and IgG-producing human myeloma ARH-77 cell lines were obtained from American Type Culture Collection, (ATCC, Rockville, MD, USA).

Techniques: Expressing, Enzyme-linked Immunosorbent Assay, Concentration Assay

BBR does not affect the viability of IgE or IgG producing cells. ( A ) The viability of IgE by IgE-producing myeloma cells, U266, was determined by trypan blue exclusion assay, following berberine (BBR) treatment at 10, 5, and 2.5 μg/mL compared to the equivalent concentration of DMSO (0 μg/mL) for 6 days. ( B ) The same was performed for IgG-producing myeloma cells, ARH-77. ( C ) Total cell count determined by Trypan Blue was used to determine total cells per mL of U266 cells and ( D ) ARH-77 cells. N = 3. BBR= Berberine. * p ≤ 0.05, ** p ≤ 0.01, ns = not significant. Each dot represents a single biological replicate.

Journal: Cells

Article Title: A Small Molecule Compound, Berberine Reduces IgE but Not IgG Production via Promoting miRNA-34a-p53 Axis

doi: 10.3390/cells14221799

Figure Lengend Snippet: BBR does not affect the viability of IgE or IgG producing cells. ( A ) The viability of IgE by IgE-producing myeloma cells, U266, was determined by trypan blue exclusion assay, following berberine (BBR) treatment at 10, 5, and 2.5 μg/mL compared to the equivalent concentration of DMSO (0 μg/mL) for 6 days. ( B ) The same was performed for IgG-producing myeloma cells, ARH-77. ( C ) Total cell count determined by Trypan Blue was used to determine total cells per mL of U266 cells and ( D ) ARH-77 cells. N = 3. BBR= Berberine. * p ≤ 0.05, ** p ≤ 0.01, ns = not significant. Each dot represents a single biological replicate.

Article Snippet: The IgE-producing human myeloma U266 cell line and IgG-producing human myeloma ARH-77 cell lines were obtained from American Type Culture Collection, (ATCC, Rockville, MD, USA).

Techniques: Trypan Blue Exclusion Assay, Concentration Assay, Cell Counting

BBR affects proliferation of IgE-producing myeloma cells with no effect on IgG-producing myeloma cells. ( A ) The proliferation of IgE by IgE-producing myeloma cells, U266, was determined by XTT assay, following berberine (BBR) treatment at 10 μg/mL compared to the equivalent concentration of DMSO (0 μg/mL) for 6 days. ( B ) The same was performed for IgG-producing myeloma cells, ARH-77. N = 3. BBR = berberine, DMSO = dimethyl sulfoxide. * p ≤ 0.05, ns = not significant. Each dot represents a single biological replicate.

Journal: Cells

Article Title: A Small Molecule Compound, Berberine Reduces IgE but Not IgG Production via Promoting miRNA-34a-p53 Axis

doi: 10.3390/cells14221799

Figure Lengend Snippet: BBR affects proliferation of IgE-producing myeloma cells with no effect on IgG-producing myeloma cells. ( A ) The proliferation of IgE by IgE-producing myeloma cells, U266, was determined by XTT assay, following berberine (BBR) treatment at 10 μg/mL compared to the equivalent concentration of DMSO (0 μg/mL) for 6 days. ( B ) The same was performed for IgG-producing myeloma cells, ARH-77. N = 3. BBR = berberine, DMSO = dimethyl sulfoxide. * p ≤ 0.05, ns = not significant. Each dot represents a single biological replicate.

Article Snippet: The IgE-producing human myeloma U266 cell line and IgG-producing human myeloma ARH-77 cell lines were obtained from American Type Culture Collection, (ATCC, Rockville, MD, USA).

Techniques: XTT Assay, Concentration Assay

BBR affects cell cycle genes of IgE-producing myeloma cells with no effect on IgG-producing myeloma cells. ( A ) qRT-PCR of IgE heavy chain ( IGHE ) and cell cycle genes cyclin D1 ( CCND1 ), tumor protein 53 ( TP53 ), and growth arrest and DNA-damage inducible alpha ( GADD45A ), in IgE-producing U266 were performed after 6 days of berberine (BBR) treatment at 10 μg/mL compared to the equivalent concentration of DMSO (0 μg/mL). qPCR analysis of cell cycle proteins of IgE-producing U266 was performed after 6 days of berberine (BBR) treatment at 10 μg/mL compared to the equivalent concentration of DMSO (0 μg/mL) and data were normalized to glyceraldehyde-3-phosphate dehydrogenase (GAPDH) expression. ( B ) The same was performed for ARH-77, with analysis of IgG heavy chain ( IGHG ). N = 3. * p ≤ 0.05, ** p ≤ 0.01, ns = not significant. Each dot represents a single biological replicate.

Journal: Cells

Article Title: A Small Molecule Compound, Berberine Reduces IgE but Not IgG Production via Promoting miRNA-34a-p53 Axis

doi: 10.3390/cells14221799

Figure Lengend Snippet: BBR affects cell cycle genes of IgE-producing myeloma cells with no effect on IgG-producing myeloma cells. ( A ) qRT-PCR of IgE heavy chain ( IGHE ) and cell cycle genes cyclin D1 ( CCND1 ), tumor protein 53 ( TP53 ), and growth arrest and DNA-damage inducible alpha ( GADD45A ), in IgE-producing U266 were performed after 6 days of berberine (BBR) treatment at 10 μg/mL compared to the equivalent concentration of DMSO (0 μg/mL). qPCR analysis of cell cycle proteins of IgE-producing U266 was performed after 6 days of berberine (BBR) treatment at 10 μg/mL compared to the equivalent concentration of DMSO (0 μg/mL) and data were normalized to glyceraldehyde-3-phosphate dehydrogenase (GAPDH) expression. ( B ) The same was performed for ARH-77, with analysis of IgG heavy chain ( IGHG ). N = 3. * p ≤ 0.05, ** p ≤ 0.01, ns = not significant. Each dot represents a single biological replicate.

Article Snippet: The IgE-producing human myeloma U266 cell line and IgG-producing human myeloma ARH-77 cell lines were obtained from American Type Culture Collection, (ATCC, Rockville, MD, USA).

Techniques: Quantitative RT-PCR, Concentration Assay, Expressing

BBR affects cell cycle genes of IgE-producing myeloma cells with no effect on IgG-producing myeloma cells. ( A ) Western Blot analysis of cell cycle genes in IgE-producing U266 was performed after 6 days of berberine (BBR) treatment at 10 μg/mL compared to the equivalent concentration of DMSO (0 μg/mL). ( B ) The same was performed for ARH-77. N = 3. CDK2 = cyclin dependent protein kinase 2, CDKN1C = cyclin dependent kinase inhibitor 1C, TP53 = tumor protein 53. * p ≤ 0.05, ** p ≤ 0.01, ns = not significant. Each dot represents a single biological replicate.

Journal: Cells

Article Title: A Small Molecule Compound, Berberine Reduces IgE but Not IgG Production via Promoting miRNA-34a-p53 Axis

doi: 10.3390/cells14221799

Figure Lengend Snippet: BBR affects cell cycle genes of IgE-producing myeloma cells with no effect on IgG-producing myeloma cells. ( A ) Western Blot analysis of cell cycle genes in IgE-producing U266 was performed after 6 days of berberine (BBR) treatment at 10 μg/mL compared to the equivalent concentration of DMSO (0 μg/mL). ( B ) The same was performed for ARH-77. N = 3. CDK2 = cyclin dependent protein kinase 2, CDKN1C = cyclin dependent kinase inhibitor 1C, TP53 = tumor protein 53. * p ≤ 0.05, ** p ≤ 0.01, ns = not significant. Each dot represents a single biological replicate.

Article Snippet: The IgE-producing human myeloma U266 cell line and IgG-producing human myeloma ARH-77 cell lines were obtained from American Type Culture Collection, (ATCC, Rockville, MD, USA).

Techniques: Western Blot, Concentration Assay

BBR affects expression of miRNAs involved in modulation of the p53 pathway of IgE-producing myeloma cells with no effect on IgG-producing myeloma cells. ( A ) miRNA isolation and qPCR analysis of miRNAs (miR) implicated IgE-regulation, miR-155, miR-143, miR-34a, and miR-146a were performed on U266 after 6 days of berberine (BBR) treatment at 10 μg/mL compared to the equivalent concentration of DMSO (0 μg/mL). ( B ) The same was performed for ARH-77. N = 3. * p ≤ 0.05, ** p ≤ 0.01, ns = not significant. Each dot represents a single biological replicate.

Journal: Cells

Article Title: A Small Molecule Compound, Berberine Reduces IgE but Not IgG Production via Promoting miRNA-34a-p53 Axis

doi: 10.3390/cells14221799

Figure Lengend Snippet: BBR affects expression of miRNAs involved in modulation of the p53 pathway of IgE-producing myeloma cells with no effect on IgG-producing myeloma cells. ( A ) miRNA isolation and qPCR analysis of miRNAs (miR) implicated IgE-regulation, miR-155, miR-143, miR-34a, and miR-146a were performed on U266 after 6 days of berberine (BBR) treatment at 10 μg/mL compared to the equivalent concentration of DMSO (0 μg/mL). ( B ) The same was performed for ARH-77. N = 3. * p ≤ 0.05, ** p ≤ 0.01, ns = not significant. Each dot represents a single biological replicate.

Article Snippet: The IgE-producing human myeloma U266 cell line and IgG-producing human myeloma ARH-77 cell lines were obtained from American Type Culture Collection, (ATCC, Rockville, MD, USA).

Techniques: Expressing, Isolation, Concentration Assay

High cytotoxicity of anti-BCMA CAR LRF-NK and PB-NK cells against BCMA-expressing cells. ( A ) Flow cytometric analysis depicts CD107a expression on anti-BCMA CAR LRF-NK cells (GFP + population) post-co-culture with U266-B1 cells (BCMA + cells). ( B ) the mean percentage of CD107a expression on anti-BCMA CAR LRF-NK cells (GFP + population) after co-culture with CCRF-CEM (BCMA − cells) and K562 cell lines. ( C ) Statistical analysis indicates significantly elevated CD107a expression on anti-BCMA CAR LRF- and PB-NK cells when co-cultured with U266-B1 compared to CCRF-CEM and K562 cells. No significant difference in CD107a expression exists between anti-BCMA CAR LRF- and PB-NK cells. Data presented as Mean ± SD. (** Represents P < 0.001, and *** P < 0.0001, N = 3). LRF: Leukocyte reduction filter. PB: peripheral blood.

Journal: Scientific Reports

Article Title: Leukoreduction filter derived NK cells offer a promising source for off the shelf CAR NK cell immunotherapy

doi: 10.1038/s41598-025-97584-1

Figure Lengend Snippet: High cytotoxicity of anti-BCMA CAR LRF-NK and PB-NK cells against BCMA-expressing cells. ( A ) Flow cytometric analysis depicts CD107a expression on anti-BCMA CAR LRF-NK cells (GFP + population) post-co-culture with U266-B1 cells (BCMA + cells). ( B ) the mean percentage of CD107a expression on anti-BCMA CAR LRF-NK cells (GFP + population) after co-culture with CCRF-CEM (BCMA − cells) and K562 cell lines. ( C ) Statistical analysis indicates significantly elevated CD107a expression on anti-BCMA CAR LRF- and PB-NK cells when co-cultured with U266-B1 compared to CCRF-CEM and K562 cells. No significant difference in CD107a expression exists between anti-BCMA CAR LRF- and PB-NK cells. Data presented as Mean ± SD. (** Represents P < 0.001, and *** P < 0.0001, N = 3). LRF: Leukocyte reduction filter. PB: peripheral blood.

Article Snippet: The human BCMA + multiple myeloma cell line (U266-B1), BCMA- acute lymphoblastic leukemia cell line (CCRF-CEM), human erythroleukemic cell line (K562), and human embryonic kidney cell line (HEK293T) were procured from the Pasteur Institute (Tehran, Iran).

Techniques: Expressing, Co-Culture Assay, Cell Culture

Specific activation of transduced NK cells. ( A ) The baseline expression levels of CD69 (upper left) on anti-BCMA CAR LRF-NK cells, when cultured alone and CD69 expression following the co-cultivation of anti-BCMA CAR LRF-NK cells with U266-B1 (upper right) CCRF-CEM (Lower Left) and K562 (lower left) cell lines. ( B ) The mean percentage of CD69 as an early activation marker significantly increased on anti-BCMA CAR LRF/PB cells following co-cultivation with the U266-B1 compared to CCRF-CEM cell lines.

Journal: Scientific Reports

Article Title: Leukoreduction filter derived NK cells offer a promising source for off the shelf CAR NK cell immunotherapy

doi: 10.1038/s41598-025-97584-1

Figure Lengend Snippet: Specific activation of transduced NK cells. ( A ) The baseline expression levels of CD69 (upper left) on anti-BCMA CAR LRF-NK cells, when cultured alone and CD69 expression following the co-cultivation of anti-BCMA CAR LRF-NK cells with U266-B1 (upper right) CCRF-CEM (Lower Left) and K562 (lower left) cell lines. ( B ) The mean percentage of CD69 as an early activation marker significantly increased on anti-BCMA CAR LRF/PB cells following co-cultivation with the U266-B1 compared to CCRF-CEM cell lines.

Techniques: Activation Assay, Expressing, Cell Culture, Marker

mRNA expression of IFN-γ ( A ) and granzyme B ( B ) in anti-BCMA CAR LRF-NK and PB-NK cells following co-culture with U266-B1 (BCMA + ), CCRF-CEM (BCMA − ), and K562 Cell Lines. The augmented expression of IFN-γ and granzyme B was evident in LRF-NK and PB-NK cells after co-cultivation with the K562 cell line, as opposed to their counterparts co-cultivated with U266-B1 and CCRF-CEM cell lines, as well as IL-2 treated NK cells. No statistically significant distinctions were discerned between LRF-NK and PB-NK cells. Conversely, Anti-BCMA CAR NK cells demonstrated a notable increase in the expression of IFN-γ and GrB after co-culture with U266-B1 compared to CCRF-CEM. The absence of significant differences between LRF and PB CAR NK cells in IFN-γ and GrB expression under identical conditions is noteworthy. Notably, a significantly heightened expression of IFN-γ and GrB in CAR NK cells compared to regular NK cells was observed after co-culture with U266-B1 cells. Data are presented as mean ± SD. (Double asterisks (**) signify P < 0.001, and triple asterisks (***) denote P < 0.0001; N = 3). LRF: leukocyte reduction filter. PB: peripheral blood.

Journal: Scientific Reports

Article Title: Leukoreduction filter derived NK cells offer a promising source for off the shelf CAR NK cell immunotherapy

doi: 10.1038/s41598-025-97584-1

Figure Lengend Snippet: mRNA expression of IFN-γ ( A ) and granzyme B ( B ) in anti-BCMA CAR LRF-NK and PB-NK cells following co-culture with U266-B1 (BCMA + ), CCRF-CEM (BCMA − ), and K562 Cell Lines. The augmented expression of IFN-γ and granzyme B was evident in LRF-NK and PB-NK cells after co-cultivation with the K562 cell line, as opposed to their counterparts co-cultivated with U266-B1 and CCRF-CEM cell lines, as well as IL-2 treated NK cells. No statistically significant distinctions were discerned between LRF-NK and PB-NK cells. Conversely, Anti-BCMA CAR NK cells demonstrated a notable increase in the expression of IFN-γ and GrB after co-culture with U266-B1 compared to CCRF-CEM. The absence of significant differences between LRF and PB CAR NK cells in IFN-γ and GrB expression under identical conditions is noteworthy. Notably, a significantly heightened expression of IFN-γ and GrB in CAR NK cells compared to regular NK cells was observed after co-culture with U266-B1 cells. Data are presented as mean ± SD. (Double asterisks (**) signify P < 0.001, and triple asterisks (***) denote P < 0.0001; N = 3). LRF: leukocyte reduction filter. PB: peripheral blood.

Techniques: Expressing, Co-Culture Assay

Review

u266 b1 human multiple myeloma b lymphocyte cell line (ATCC)

Structured Review

Images

Related Articles

Cell Culture:

other:

FACS:

Similar Products

Image Search Results